This is the protocol for a review and there is no abstract. The objectives are as follows:
This review aims to look at the benefits and harms of different forms of fluid and/or diuretic therapy used for preventing cisplatin-induced nephrotoxicity in patients treated for neoplastic diseases. It will try to identify the most effective regimen. An attempt will be made to establish a lower and/or upper limit of fluid volume to be used. The heterogeneity of the patient populations regarding e.g. different dosages and treatment schedules will be taken into account in the analysis of the data.